EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)

Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study)

I Caramella, A Dalla Volta, F Valcamonico, M Bergamini, M Buffoni, A Zivi, G Procopio, P Sepe, N Di Meo, S Foti, S Zamboni, C Messina und 11 weitere

Bone · 2026

DOI: 10.1016/j.bone.2026.117906 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Bone, 2026. Verfasst von I Caramella und 22 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, U…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Phenylthiohydantoin, Androgen Antagonists, Diphosphonates. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Associazione Italiana per la Ricerca sul Cancro, Astellas Pharma US Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsPhenylthiohydantoinAndrogen AntagonistsDiphosphonatesImidazolesBone and BonesHumansMaleZoledronic AcidNitrilesBone DensityAgedBenzamidesAbsorptiometry, PhotonCollagen Type IMiddle AgedNeoplasm MetastasisBone Neoplasms

Stichwörter der Autor:innen

ALPBone biomarkersBone healthCTXEnzalutamideProstate cancerZoledronic acid

Substanzen

Zoledronic AcidNitrilesPhenylthiohydantoinenzalutamideAndrogen AntagonistsBenzamidesDiphosphonatesImidazolesCollagen Type I

Autor:innen und Institutionen

  • Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
  • Unit of Medical Oncology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy. Electronic address: alberto.dall…
  • Section of Innovation Biomedicine - Oncology Area, Department of Engineering for Innovation Medicine, University of Verona, Verona University and Hospital Trust (AOUI), Verona, Italy.
  • Medical Oncology Department, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, Italy.
  • Unit of Radiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili di Brescia, University of Brescia, Brescia, Italy.
  • Department of Oncology, Fondazione IRCCS San Raffaele Hospital, Milan, Italy.

Förderung

  • Associazione Italiana per la Ricerca sul Cancro
  • Astellas Pharma US Inc

Zitieren

APA

Caramella, I., Dalla Volta, A., Valcamonico, F., Bergamini, M., Buffoni, M., Zivi, A., Procopio, G., Sepe, P., Di Meo, N., Foti, S., Zamboni, S., Messina, C., Rizzi, A., Lucchini, E., Ravanelli, M., Zamparini, M., Zacchi, F., Laganà, M., Cosentini, D., …, & Berruti, A. (2026). Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study). Bone. https://doi.org/10.1016/j.bone.2026.117906

Vancouver

Caramella I, Dalla Volta A, Valcamonico F, Bergamini M, Buffoni M, Zivi A, et al. Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study). Bone. 2026. doi:10.1016/j.bone.2026.117906

BibTeX
@article{Caramella2026,
  author = {Caramella, I and Dalla Volta, A and Valcamonico, F and Bergamini, M and Buffoni, M and Zivi, A and Procopio, G and Sepe, P and Di Meo, N and Foti, S and Zamboni, S and Messina, C and Rizzi, A and Lucchini, E and Ravanelli, M and Zamparini, M and Zacchi, F and Laganà, M and Cosentini, D and Bresciani, R and Suardi, N and Farina, D and Berruti, A},
  title = {Multiparametric assessment of bone health in metastatic hormone-sensitive prostate cancer patients receiving androgen deprivation + enzalutamide ± zoledronic acid (BonEnza study)},
  journal = {Bone},
  year = {2026},
  doi = {10.1016/j.bone.2026.117906}
}
Kostenlos starten →